Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Drug Resistance Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GSTP1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GSTP1 Active Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. E. coli expressed. |
View GSTP1 Products |
| Gene Delivery | GSTP1 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression studies. |
View GSTP1 Products |
| Benchmark Ab | Anti-GSTP1 Recombinant Antibody High-affinity positive control for Western Blot, ELISA, and IHC. |
View GSTP1 Products |
| Validator | GSTP1 siRNA Set Target-specific knockdown verification in drug-resistant cell lines. |
View GSTP1 Products |
| Related Target A | JNK1 GSTP1 physically interacts with JNK1 to inhibit its phosphorylation, regulating apoptosis. |
View JNK1 Products |
| Related Target B | GSR Glutathione Reductase maintains the pool of reduced glutathione (GSH) required for GSTP1 activity. |
View GSR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GST Family Selectivity (Avoiding GSTA/GSTM off-target) | Homolog panel of GSTA1, GSTM1, and GSTP1 proteins strictly verified by mass spectrometry. |
| Enzymatic Assay Reproducibility | Enzymatically active GSTP1 recombinant proteins with optimized specific activity parameters. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-affinity reference clones included. |
| False Positives | Multi-sequence validated siRNA sets for precise target specificity validation. |
Live GSTP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GSTP1 therapeutics is intensifying, with major players shifting focus from traditional non-selective alkylating agents to highly targeted small-molecule inhibitors, PROTACs, and GSTP1-activated prodrugs. As first-generation therapies reach the clinic, the next wave of R&D is targeting the reversal of multi-drug resistance (MDR) in platinum-resistant solid tumors, where GSTP1 overexpression acts as a key survival mechanism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Telik, Academic Spin-offs | Ovarian Cancer, Colorectal Cancer | Selectivity Assay (Need high-purity GSTP1 vs GSTM1/GSTA1 proteins) |
| GSTP1-Activated Prodrugs | Biotech Consortia | Platinum-Resistant Solid Tumors | Enzymatic Cleavage Assay (Need highly active, sequence-verified GSTP1) |
| Targeted Protein Degradation (PROTAC) | Oncology Startups | Prostate Cancer, Triple-Negative Breast Cancer | Target Engagement & Ternary Complex Validation (Need pure GSTP1 & antibodies) |